Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05052970 | Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | unknown | Phase 1 | 60 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05160714 | Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI(MRL-02) | unknown | Phase 1 | 24 | University Hospital TuebingenOTHER | 1 | Feb 1, 2022 |
| clinicaltrials |
| NCT04233840 | P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 72 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05211557 | Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | unknown | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02675946 | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | unknown | Phase 1 | 72 | Curegenix Inc.INDUSTRY | 2 | Jan 26, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05198531 | To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer | unknown | Phase 1 / Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05198856 | Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC | unknown | Phase 1 / Phase 2 | 106 | Qilu Hospital of Shandong UniversityOTHER | 0 | Jan 20, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05049083 | A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects | unknown | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05108077 | Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | unknown | Phase 1 / Phase 2 | 20 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05008575 | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04384393 | Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04608786 | A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer | unknown | Phase 1 | 10 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05158491 | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | unknown | Phase 1 / Phase 2 | 63 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT03821519 | Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant(Haplo-CIK) | unknown | Phase 1 / Phase 2 | 20 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT04282070 | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 | 91 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05164042 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05157542 | Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC | unknown | Phase 1 | 9 | Juan LI, MDOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05156424 | A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Kira MurphyOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05068921 | A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05124106 | In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours | unknown | Phase 1 | 30 | University Hospital Bispebjerg and FrederiksbergOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05139082 | Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors | unknown | Phase 1 / Phase 2 | 60 | Peking UniversityOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05108012 | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | unknown | Phase 1 | 5 | Royan InstituteOTHER_GOV | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05127135 | Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT03847168 | KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer | unknown | Phase 1 | 22 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Nov 17, 2021 | clinicaltrials |
| NCT05123209 | Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors | unknown | Phase 1 | 12 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04443296 | Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma(TIL-Cx) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04810910 | Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | unknown | Phase 1 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04014894 | ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma | unknown | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04818372 | Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | unknown | Phase 1 | 87 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT05106946 | Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | unknown | Phase 1 | 20 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT04973098 | Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma | unknown | Phase 1 | 13 | Peking UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2022source: clinicaltrials